• LinkedIn
  • Twitter
  • Pinterest
  • Vimeo
  • Skype
  • Youtube
  • Rss
  • Home
  • Events
  • Careers at CAPTIS
  • Log In / Sign In ▼
    • Log In with LinkedIn
    • Register w/out LinkedIn
    • Login w/out LinkedIn
    • Reset Lost Password
  • 🔒 MEMBER AREA ▼
    • View your profile
    • Edit your profile
    • Log out
       ☎ US Offices 1 (800) 445-1839 Toll Free | Europe/Int'l +41 22 518 2100
CAPTIS Executive Search
  • CAPTIS
  • You are a Business
    • Executive Search
    • Our Commitments
    • Other Services
    • Our Locations
    • About Us
    • Key Values
  • You are a Healthcare Executive
    • Dealing with CAPTIS
    • Candidate Contact Form
    • Login with LinkedIn
    • Create an Account
    • Log in (Existing Account)
    • WW Trade Shows
      • Medical & Pharmaceutical
      • Orthopedics
      • Spine
      • Cardiovascular
      • Diagnostics
      • Wound Care
      • Plastic & Aesthetic Surgery
      • Surgery
      • Trauma
      • Pediatric Care
    • Industry News
      • News
      • Wall Street Beat
      • Business/Financial News
      • Clinical Trials
      • Musculoskeletal News Roundup
      • Cardiovascular
      • M&A Activity
      • Food & Drug Administration (FDA)
      • Wound Care
      • Practice Management
  • CAPTIS Magazine
    • Healthcare News
    • @CaptisCorp Twitter Timeline
    • Healthcare Events
    • CAPTIS LinkedIn Timeline
    • Articles ➜
      • Recruiting
      • Personal Development
      • News
  • Make an Inquiry
  • Contact Us
    • General Contact Form
    • Healthcare Executive Contact
    • Apply for a position at CAPTIS
    • Call 1 800 445 1839
      (Cell/Mobile US & Canada Toll Free, or Skype)
    • Call +41 22 518 2100
      (Cell/Mobile Swiss Landline Switchboard, or Skype)
  • Search
  • Menu Menu

CAPTIS – Executive Search & Management Consulting

Captare. Aestimare. Eligere. Succedere.

You are a Business

You are an Executive

Want to work at CAPTIS

Learn about our services

 

 

Executive Search
Submit an inquiry

Create and/or update

your confidential profile

 

Executive’s General Information
Create an account & Add your profile

Go to our Careers page

 

 

CAPTIS Careers

Recent Healthcare News:

11/27/2020

Haoma Medica completes first-in-human trial for NaQuinate

The first-in-human trial initiated last year in healthy adults…
11/27/2020

EMA validates application for Tepotinib for treatment of advanced NSCLC with METex14 skipping alterations

11/27/2020

Astellas gets Japanese approval for Evrenzo to treat anaemia of CKD in adult patients not on dialysis

11/26/2020

Celltrion completes enrolment for global phase II clinical trial with Covid-19 treatment candidate

11/26/2020

FDA defers approval of DaxibotulinumtoxinA for Injection in glabellar lines due to Covid-19 related travel restrictions

11/26/2020

EC approves Moderna’s purchase agreement for mRNA Covid-19 vaccine

11/25/2020

FDA approves Roche’s Xofluza to prevent influenza following contact with infected person

11/25/2020

Apnimed doses first patient in phase 2 trial of AD109 in obstructive sleep apnea

11/25/2020

Health Canada clears Appili Therapeutics for new phase 3 trial to assess Avigan to prevent Covid-19

11/25/2020

City of Hope begins phase 1 clinical trial of Covid-19 vaccine candidate

11/24/2020

GSK begins patient dosing in phase 3 trial of RSV maternal candidate vaccine

RSV is responsible for respiratory infections such as bronchiolitis…
11/24/2020

Pfizer doses first participant in phase 3 study evaluating anti-TFPI investigational therapy

11/24/2020

HiFiBiO partners with Pharmsynthez and IBCh to develop and commercialise SARS-CoV-2 neutralising antibody in Russia

11/24/2020

Merck to buy biopharmaceutical firm OncoImmune for $425m

11/23/2020

ADC Therapeutics secures FDA priority review for Lonca in diffuse large B-cell lymphoma

11/23/2020

AstraZeneca’s AZD1222 vaccine demonstrates promising efficacy

11/23/2020

Clear Creek Bio doses first patient in phase 2 outpatient study of Brequinar to treat Covid-19

11/23/2020

Pfizer, BioNTech seek FDA EUA status for Covid-19 vaccine

11/20/2020

Zymeworks gets EC’s orphan drug designation for zanidatamab in patients with gastric cancer

11/20/2020

Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy

Go to the Healthcare News

Recent news from your industry: Finance, M&A, Products, Companies and more…

Upcoming Events:

We Suggest:

Eli Lilly, Incyte get FDA EUA status for baricitinib plus remdesivir to treat Covid-19

0 Comments
/
11/20/2020
The EUA status facilitates distribution and emergency use of…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-20 01:01:092020-11-20 01:01:10Eli Lilly, Incyte get FDA EUA status for baricitinib plus remdesivir to treat Covid-19

FDA clears expanded access IND for APT’s PhageBank therapy for Covid-19-related bacterial infections

0 Comments
/
11/19/2020
“The FDA’s decision supports our ability to provide a new…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-19 04:31:122020-11-19 04:31:12FDA clears expanded access IND for APT’s PhageBank therapy for Covid-19-related bacterial infections

Rilzabrutinib granted FDA fast track designation for treatment of immune thrombocytopenia

0 Comments
/
11/19/2020
In addition, following positive Phase 1/2 study results, a Phase…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-19 03:31:072020-11-19 03:31:07Rilzabrutinib granted FDA fast track designation for treatment of immune thrombocytopenia

Pfizer, BioNTech’s Covid-19 vaccine candidate meets all primary efficacy endpoints in phase 3 study

0 Comments
/
11/19/2020
The data analysis showed a vaccine efficacy rate of 95% in participants…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-19 02:01:262020-11-19 02:01:27Pfizer, BioNTech’s Covid-19 vaccine candidate meets all primary efficacy endpoints in phase 3 study

Bristol Myers Squibb wraps up acquisition of MyoKardia

0 Comments
/
11/18/2020
With the closing of the deal, MyoKardia now operates as a wholly-owned…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-18 04:31:352020-11-18 04:31:36Bristol Myers Squibb wraps up acquisition of MyoKardia

Cerebral Therapeutics announces enrolment of first patient in phase 2b trial in epilepsy

0 Comments
/
11/18/2020
The trial is enrolling adult epilepsy patients with temporal…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-18 04:31:342020-11-18 04:31:35Cerebral Therapeutics announces enrolment of first patient in phase 2b trial in epilepsy

Moderna announces supply agreement with UK government to supply Covid-19 mRNA vaccine

0 Comments
/
11/18/2020
This agreement comes as the UK continues its efforts to secure…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-18 03:31:112020-11-18 03:31:12Moderna announces supply agreement with UK government to supply Covid-19 mRNA vaccine

ViiV Healthcare gets FDA breakthrough therapy status for HIV prevention drug cabotegravir

0 Comments
/
11/18/2020
The status was based on efficacy and safety results from HPTN…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-18 02:01:142020-11-18 02:01:15ViiV Healthcare gets FDA breakthrough therapy status for HIV prevention drug cabotegravir

Merck advances phase 3 trial for islatravir as once-monthly oral PrEP for women at high risk for acquiring HIV-1

0 Comments
/
11/17/2020
The study, IMPOWER 22, will evaluate the efficacy and safety…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-17 04:31:332020-11-17 04:31:34Merck advances phase 3 trial for islatravir as once-monthly oral PrEP for women at high risk for acquiring HIV-1

Amylyx announces FDA granted orphan drug designation for AMX0035 to treat Wolfram syndrome

0 Comments
/
11/17/2020
“There is a critical unmet need for people living with Wolfram…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-17 04:01:292020-11-17 04:01:29Amylyx announces FDA granted orphan drug designation for AMX0035 to treat Wolfram syndrome

Inovio secures FDA nod for phase 2 segment of Covid-19 DNA vaccine candidate trial

0 Comments
/
11/17/2020
The phase 2 segment will evaluate the efficacy of Covid-19 DNA…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-17 04:01:292020-11-17 04:01:30Inovio secures FDA nod for phase 2 segment of Covid-19 DNA vaccine candidate trial

Moderna’s Covid-19 vaccine candidate shows 94.5% efficacy in phase 3 COVE study

0 Comments
/
11/17/2020
The independent and NIH-appointed Data Safety Monitoring Board…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-17 02:32:542020-11-17 02:32:55Moderna’s Covid-19 vaccine candidate shows 94.5% efficacy in phase 3 COVE study

Roche, Lead Pharma partner to develop oral small molecules for immune-mediated diseases

0 Comments
/
11/16/2020
As part of single target research collaboration, both companies…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-16 04:31:222020-11-16 04:31:22Roche, Lead Pharma partner to develop oral small molecules for immune-mediated diseases

Lupin announces FDA filing acceptance of sNDA for Solosec to treat trichomoniasis

0 Comments
/
11/16/2020
The FDA has assigned a Prescription Drug User Fee Act (PDUFA)…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-16 04:31:222020-11-16 04:31:23Lupin announces FDA filing acceptance of sNDA for Solosec to treat trichomoniasis

Vicore Pharma recruits the first patient in the phase 2 proof-of-concept study in idiopathic pulmonary fibrosis

0 Comments
/
11/16/2020
Dr. Himanshu Pop Hale, Ace Hospital Pune, India, has recruited…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-16 04:31:212020-11-16 04:31:21Vicore Pharma recruits the first patient in the phase 2 proof-of-concept study in idiopathic pulmonary fibrosis

Merck gets first FDA nod for Keytruda in breast cancer setting

0 Comments
/
11/16/2020
Keytruda (pembrolizumab), an anti-PD-1 therapy, works by enhancing…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-16 02:31:082020-11-16 02:31:09Merck gets first FDA nod for Keytruda in breast cancer setting

AstraZeneca’s Calquence fails to meet primary efficacy endpoint in phase II Covid-19 trials

0 Comments
/
11/12/2020
The addition of Calquence to best supportive care (BSC) has failed…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-12 21:01:172020-11-12 21:01:17AstraZeneca’s Calquence fails to meet primary efficacy endpoint in phase II Covid-19 trials

Sagent Pharmaceuticals launches phase 2 trial to evaluate Camostat Mesilate for Covid-19 treatment

0 Comments
/
11/12/2020
“We thank the FDA for expediting our new Investigational…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-12 03:31:112020-11-12 03:31:11Sagent Pharmaceuticals launches phase 2 trial to evaluate Camostat Mesilate for Covid-19 treatment

Russia’s Sputnik V vaccine shows 92% efficacy in phase III Covid-19 trials

0 Comments
/
11/12/2020
The interim analysis showed that Sputnik V vaccine has shown…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-12 01:01:222020-11-12 01:01:23Russia’s Sputnik V vaccine shows 92% efficacy in phase III Covid-19 trials

Tezepelumab NAVIGATOR trial in severe, uncontrolled asthma patients meets primary endpoint

0 Comments
/
11/11/2020
NAVIGATOR met the primary endpoint with tezepelumab added to…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-11 04:31:102020-11-11 04:31:10Tezepelumab NAVIGATOR trial in severe, uncontrolled asthma patients meets primary endpoint
PreviousNext

  • Thorough Network

  • Deep Knowledge

  • Comprehensive Process

  • Ethical Approach

  • Confidentiality

  • Assessment Capacity

99%

Percentage of successful project completion

85%

Of placed executives remain with the client company 3 or more years

  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

Archives

Follow CAPTIS



CAPTIS
Followon TwitterSubscribeto RSS Feed

We Recommend

Our very best and up-to-date selection of healthcare Industries' News (Products, Markets, Companies, R&D, Technology, Opportunities, Investment & Finance...).
Read at Healthcare News

CAPTIS Newsletter

Call CAPTIS

United States Offices
1 (800) 445-1839

(United States & Canada Toll Free)

Europe & International
+41 22 518 2100

© CAPTIS - Executive Search - 2017 - [email protected]
  • LinkedIn
  • Twitter
  • Pinterest
  • Vimeo
  • Skype
  • Youtube
  • Rss
  • Events
  • For Healthcare Executives
  • Legal & Privacy Notes, GDPR & Cookies Policy
  • Client Area
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OK, got itCookies Policy
Scroll to top